HK
0
Active Trials
0
Total Trials
0
Organizations
0
Events

Hong Kong

Medical Only (Private)

Reimbursed Care Access

Hong Kong maintains a strict, prohibition-oriented regulatory regime for most classic psychedelics under the Dangerous Drugs Ordinance, while permitting medical use of ketamine (as an anaesthetic) and, more recently, regulated clinical availability of esketamine (intranasal) through the public Hospital Authority formulary and private clinics. Most other listed compounds (psilocybin, MDMA, DMT, 5‑MeO‑DMT, ibogaine, ayahuasca, mescaline, 2C‑X) remain controlled as "dangerous drugs" with no authorised therapeutic access outside of tightly controlled research or approved medical channels.

No clinical trials found for this country yet.

Research Events